A new treatment may revolutionize how melanoma is treated. Melanoma is by far the deadliest form of skin cancer, capable of metastizing much faster than any other form of skin malignancy.
An injectible compound, known as PV-10, has been shown to shrink tumors and block metastization in melanomas, thereby reducing the spread of the cancer.
PV-10 is a solution derived from Rose Bengal, a dye used to stain damaged cells in the eye. It has shown in studies to enhance immune response in melanoma and the blood stream.
There are currently many different treatments for melanoma, but PV-10 seems to be the most promising to date.
The initial study was done in mice who had developed melanoma. The research showed that those mice who had been injected showed a marked reduction in cancer lesions, and a considerable reduction of the tumors that had already metastized to the lungs.
The compound, in addition, is safer than almost any other treatment available on the market today for melanoma.
The first human clinical trial of PV - 10 is well on its way right now, and this is very important for a quick adoption and introduction of the compound for wide use. The human trial is also important because it measures the immune response boost in the cells of patients after treatment with PV-10.
An open access essay of the study is available online in PLOS ONE, and it is sponsored by Provectus Pharmaceuticals inc, who are the developers of the compound.
Source : MNT/ 8.26.13
No comments:
Post a Comment